According to the data available on the PHAROS web interface for exploring target/ligand interactions [168], for the query ”RUNX2”, currently, there are no approved drugs or active ligands (ChEMBL compounds with an activity cutoff of <30 nM) available, so clinical trials focusing on testing RUNX2 based-drugs in HCC and in tumours in general are still an unexplored field. This evidence concerns the gene RUNX2 and hepatocellular carcinoma.